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Edita Kriukiene1,*, Viviane Labrie2,*, Tarang Khare2, Giedre Urbanavičiu-te1, Audrone Lapinaite1,w,
Karolis Koncevičius3, Daofeng Li4, Ting Wang4, Shraddha Pai2, Carolyn Ptak2, Juozas Gordevičius5,
Sun-Chong Wang6, Artu-ras Petronis2 & Saulius Klimašauskas1

Dynamic patterns of cytosine-5 methylation and successive hydroxylation are part of
epigenetic regulation in eukaryotes, including humans, which contributes to normal phenotypic variation and disease risk. Here we present an approach for the mapping of unmodiﬁed
regions of the genome, which we call the unmethylome. Our technique is based on DNA
methyltransferase-directed transfer of activated groups and covalent biotin tagging of
unmodiﬁed CpG sites followed by afﬁnity enrichment and interrogation on tiling microarrays
or next generation sequencing. Control experiments and pilot studies of human genomic DNA
from cultured cells and tissues demonstrate that, along with providing a unique cross-section
through the chemical landscape of the epigenome, the methyltransferase-directed transfer of
activated groups-based approach offers high precision and robustness as compared with
existing afﬁnity-based techniques.
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D

NA cytosine-5 methylation is a widespread epigenetic
mark in high eukaryotes including mammals. DNA
methylation proﬁles are highly variable across different
genetic loci, cells and organisms, and are dependent on tissue,
age, sex, diet and disease1,2. In somatic cells, 5-methylcytosine
(5mC) is largely restricted to CpG sites3. Recent studies of
vertebrate DNA found that 5mC residues can undergo oxidation
to 5-hydroxymethylcytosine (hmC), 5-formylcytosine (fC) or
5-carboxycytosine (caC) in a tissue- and locus-speciﬁc manner4.
Existing approaches for the determination of the modiﬁcation
status of CpG sites are largely based on detection of 5mC and can
be divided into bisulﬁte conversion-based methods, afﬁnity
capture-based techniques and restriction endonuclease-based
methods5–8. The gold standard is bisulﬁte conversion coupled
with sequencing due to its ability to map 5-modiﬁed cytosines at a
single-base resolution9,10. However, bisulﬁte conversion displays
fC and caC as unmodiﬁed C, and discrimination between 5mC
and hmC requires additional cumbersome pretreatment
steps11,12. Overall, it is a labour-intensive technique3,13 that is
still prohibitively expensive for large-scale populational studies. In
afﬁnity enrichment methods, methylated DNA fragments are
non-covalently bound to 5mC-antibodies (MeDIP)6 or to the
methyl-CpG binding domain of MBD2 or MeCP2 (refs 14,15).
The latter methods suffer from a poor coverage of the medium to
low CpG density regions of the genome16,17. Restriction enzymebased approaches permit interrogation of either the unmodiﬁed
or modiﬁed fraction of genomic DNA (gDNA)5,8,18–21, however,
their coverage and resolution is inherently limited by the
sequence- and modiﬁcation-type-speciﬁcity of available
enzymes. Therefore, none of the existing methods alone is able
to grasp the breath and chemical complexity of the mammalian
epigenome.
To circumvent these limitations, we pursued a novel strategy
for determining the genome modiﬁcation status that is based on
covalent labelling of unmodiﬁed CpG sites. Targeted labelling of
DNA was achieved by using a recently devised chemo-enzymatic
approach named ‘methyltransferase-directed transfer of activated
groups’ (mTAG)22 followed by chemoselective biotinylation of
the attached terminal amine or azide groups. The labelled
genomic fragments were selectively enriched on streptavidin
beads and analysed on tiling microarrays and next generation
sequencing. Studies of human gDNA from cultured cells and
tissues demonstrate that this technique offers nanogram
sensitivity, as well as high precision and reproducibility.
Notably, we demonstrate that mTAG-based methods uniquely
permit a positive identiﬁcation of unmethylated loci in various
complex genomic contexts such as repeat sequences and partially
methylated regions.
Results
General approach for covalent capture of genomic CpG sites.
Previously, we demonstrated that the HhaI DNA cytosine-5
methyltransferase, which serves as a structural and mechanistic
paradigm for this class of enzymes, can be engineered to
direct efﬁcient transfer of extended linear groups from synthetic
AdoMet analogues onto the GCGC sites in DNA23,24. Following
this concept, we engineered the CpG-speciﬁc cytosine-5 MTase
SssI (M.SssI)25, by site directed mutagenesis of two conserved
positions in the cofactor-binding pocket (Q142A/N370A).
The recombinant His-tagged protein was expressed in E. coli
and isolated in an AdoMet-free form (Supplementary Methods).
We have also synthesized a series of optimized AdoMet analogues
that contain a sulfonium-bound 6-substituted hex-2-ynyl
side chain26. The engineered M.SssI (eM.SssI) exhibited a
higher than 100-fold increase in the alkylation activity with
2

these synthetic cofactors (Supplementary Fig. S1) as compared
with native M.SssI. As the MTase-directed reactions are highly
speciﬁc with respect to the target sequence, modiﬁed residue
and atomic position22,27, the M.SssI-directed mTAG labelling
selectively tags all unmodiﬁed and hemimethylated CpG sites25
and excludes methylated target sites (5mCpG) in gDNA.
In this study, two biotin conjugation chemistries were explored
(Fig. 1b). In the ﬁrst series, conventional chemoselective coupling
of a primary alifatic amine group, which are absent from native
DNA, with a biotin probe carrying an N-hydroxysuccinimide
(NHS) group was employed (Supplementary Fig. S2). Alternatively, we used a fully bioorthogonal copper-free click-chemistry,
namely Huisgen 1,3-dipolar cycloaddition of azide to a ringactivated alkyne, dibenzocyclooctyne group (DBCO)28. In both
cases, a biotin linker containing a cleavable S-S bond was present
to facilitate the detachment of the captured DNA fragments.
mTAG labelling using amine-NHS chemistry. The general
procedure for the enrichment of unmodiﬁed DNA consisted of
ﬁve steps (Fig. 1a). Human gDNA was sonicated to yield short
(50–300 bp) fragments (Step 1), aminoalkylated with eM.SssI and
Ado-6-amine (Step 2), biotinylated with an amino-reactive
reagent NHS-SS-biotin (Step 3) and captured on streptavidin
beads (Step 4). In our initial control experiments that measured
the levels of labelling and DNA capture (Steps 2–4) by quantitative PCR (qPCR), we designed a series of 200–230 bp DNA
fragments containing none, 1, 2 or 4 unmodiﬁed CpG sites
(probes 0-CG, 1-CG, 2-CG and 4-CG, respectively; Fig. 2a). These
DNA fragments were tested individually and as spike-ins to
sonicated gDNA samples. Robust mTAG labelling produced CpG
capture efﬁciencies around 90%, whereas a 0-CG spike was
detectable at a level of B1% (Fig. 1c). In subsequent experiments
designed to optimize the procedure, three levels of mTAG
labelling intensity (as determined by the streptavidin capture
efﬁciency of the 2-CG probe) were explored: 5–10% capture-low
labelling; 20–35% capture-medium labelling; 60–80% capturehigh labelling. It was found that, at medium labelling, the capture
of the model DNA fragments linearly correlated with the number
of unmodiﬁed CpG sites (Fig. 2b), an effect that persisted in the
presence of methylated DNA fragments (Supplementary Fig. S3)
and upon deep dilution with native gDNA (Fig. 2c). Efﬁcient
recovery of streptavidin-bound DNA (Step 5) was achieved via
mild chemical cleavage of a disulphide bond in the biotin connector with dithiothreitol (DTT). The released DNA fragments
retain only a part of the original linear side chain attached to the
labelled cytosine residues (Fig. 1b and Supplementary Fig. S2),
which did not interfere with downstream PCR ampliﬁcation
(Supplementary Fig. S4).
To assess the performance of this new technology for
epigenome studies, we carried out further control experiments
with sheared human gDNA in which all cytosine modiﬁcations
were stripped by PCR ampliﬁcation. These ‘fully unmodiﬁed’
DNA samples were mTAG-labelled, with separate aliquots for the
low, medium and high labelling intensities and bound to
streptavidin beads. The enriched DNA samples were PCRampliﬁed and analysed on a human genome tiling microarray (E
array covering chromosomes 5, 7 and 16 from the Affymetrix
2.0 R whole-genome human tilling microarray set). Probe
intensities for chromosome 5 (2.6 million probes covering 1,013
genes and 1,227 CpG islands) were scale normalized and
averaged. Optimal performance was again observed at the
medium labelling intensity of around 25%, although in general,
variations in the range of 10–80% showed rather small changes in
the mean signal proﬁle (Fig. 3a). The relationship of the mean log
array signal intensity versus the local CpG density was linear
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Figure 1 | mTAG labelling-based enrichment and analysis of unmethylated CpG sites in the genome. (a) Flow diagram of the analytical procedure.
gDNA is randomly sheared to short fragments (Step 1) and treated with an engineered SssI DNA methyltransferase (eM.SssI) and a cofactor
analogue (Ado-6-amine or azide) to attach reactive groups to unmodiﬁed CpG sites (Step 2). The derivatized target sites are biotin-tagged using
N-hydroxysuccinimidyl ester (Biotin-SS-NHS) (Step 3) and labelled fragments are selectively captured on streptavidin-coated magnetic beads (Step 4).
Bound DNA fragments are recovered by cleavage of a disulphide bond in the biotin linker with DTT (Step 5). The enriched fragments are ligated to adaptors
and PCR-ampliﬁed (Step 6) for microarray analysis or DNA sequencing (Step 7). (b) Covalent transformations during derivatization, biotin tagging
and linker cleavage (Steps 2, 3 and 5) using amine-NHS (upper) or azide-DBCO (lower) conjugation chemistries (one of the two triazol regioisomers
formed in Step 3 is shown); (c) Afﬁnity capture of DNA fragments containing unmodiﬁed CpG sites. Reference DNA fragments, containing two or no CpG
sites (2-CG and 0-CG, respectively) was each combined with 300 ng of sonicated human gDNA and processed as described (Steps 1–4) using the amine
or azide conjugation chemistries as indicated. The efﬁciency of CpG capture is assessed by on-beads qPCR analysis of the reference DNA fragments.
Error bars deﬁned as ±s.d. from duplicate experiments.

(r ¼ 0.99) in the range from 0 to 10 unmethylated CpG sites per
200 bp fragment (Fig. 3a), and then reached a plateau at higher
CpG densities. Given that 87% of the genome contains 10 or less
CpGs per 200 bp (Fig. 3b) and only 20–30% of CpGs are
unmodiﬁed29, the overwhelming majority of native gDNA
fragments should fall within the linear mTAG labelling and
interrogation range.
Next, we analysed native gDNA samples using mTAG-based
enrichment coupled with interrogation on tiling arrays (mTAGchip). mTAG enrichment of the DNA unmethylome from human
tissues showed low technical variation (typical correlations in the
range of 0.89–0.93). Analysis of the mTAG-chip proﬁles
consistently detected known unmethylated genomic regions
(Supplementary Fig. S5) that showed strong associations with
histone acetylation and H3K4 methylation—marks of active
promoters and functional enhancers30 (Supplementary Fig. S6).
We also performed a rigorous quantitative comparison of
the mTAG approach with published data sets from methylationsensitive restriction enzyme sequencing (MRE-seq), MBD-seq

and MeDIP-seq experiments8 using IMR90 and H1 MethylC-seq
maps3 as the gold standard. For this, fetal lung ﬁbroblast (IMR90)
gDNA (gift of R. Lister) was assessed in the mTAG procedure.
Correlation analyses with the IMR90 MethylC-seq map at
sequencing depths of 45, 410 or 415 reads (with effective
genome coverage of 62%, 35% and 19%, respectively) were carried
out for 1,000, 400 or 200 bp-sized windows and were stratiﬁed
across deciles of local CpG densities (Fig. 4a; Supplementary Fig.
S7). Depending on the decile, correlation coefﬁcients varied from
0.14 to 0.31 (Fig. 4a). In MRE-seq, MBD-seq and MeDIP-seq
experiments on H1 human embryonic stem cells3 with the
corresponding reference MethylC-seq map8, we found
correlations to be close to 0, except at the highest CpG density
decile (Fig. 4a). Altogether, mTAG-chip proved superior to the
other methods in 8 or even 9 CpG density deciles representing
80–90% of the human genome and 50–68% of all CpGs
(Supplementary Table S2). Similarly, a concordance analysis
showed that mTAG-chip achieves better parameters than
MeDIP-chip (Fig. 4b). Notably, the overall precision in
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Figure 2 | Streptavidin capture of unmodiﬁed CpG sites in model DNA fragments. (a) Schematic of nonspeciﬁc (containing no CpG sites, 0-CG) and
speciﬁc (containing 1, 2 or 4 CpG sites) DNA probes derived from the mouse genome for quantiﬁcation of DNA using TaqMan qPCR. CpG sites are shown
in black and locations of qPCR primers are shown as arrows. ‘m‘ denotes a premethylated CpG site. (b) DNA recovery through Steps 1–4. DNA probes
(25 ng) as indicated were combined with 300 ng of sheared and blunt-ended gDNA and then mTAG-labelled at Medium Intensity (top, amine-NHS
conjugation chemistry; bottom, azide-DBCO conjugation chemistry). DNA was further processed as described in Methods and the amount of captured
DNA was determined in qPCR analysis. (c) DNA recovery through Steps 1–4 in a series of 10-fold dilutions (1:10–1:1,000,000). A speciﬁed amount of
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azide-DBCO conjugation chemistry). DNA was further processed as described and the amount of captured DNA was determined by qPCR analysis.
Error bars deﬁned as ±s.d. from duplicate experiments.
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mapping the DNA methylome increases signiﬁcantly in an
‘integrative’ mTAG/MeDIP-chip experiment, even in the regions
of higher CpG density, where both techniques are similarly
faithful.
The large difference in correlation between mTAG-chip and the
MRE-, MeDIP- and MBD-sequencing-based methods prompted us
to verify if the observed differences arose because of distinct
platforms. We therefore performed DNA methylome analysis of
the IMR90 gDNA using MeDIP-chip. The observed MeDIP-chip
correlations were lower than the ones of the mTAG-chip, however,
the former showed signiﬁcantly higher correlations to MethylC-seq
4

in comparison to the MRE-seq, MBD-seq and MeDIP-seq data sets
(Fig. 4a; Supplementary Fig. S7). The reasons for the low
correlation (o0.4) between the MethylC-seq and the enriched
microarray and sequencing-based data sets were not completely
clear. In part, it may derive from an insufﬁcient x-fold coverage of
the methylome in the MethylC-seq experiment (only 19% of the
genome covered at 415 reads), which is required to offset an
inherent unevenness of DNA sequencing31. Depending on the
degree of intra-individual variation of DNA modiﬁcation, the
minimal coverage may vary dramatically from locus to locus and
may often require as many as 50–60 reads32.
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Figure 4 | Comparison of the mTAG approach with existing methylome proﬁling methods. (a) Pearson correlations between experimental mTAG-chip
(amine-NHS chemistry), MeDIP-chip of IMR90 gDNA and published data of MeDIP-seq, MBD-seq, MRE-seq analysis of H1 gDNA8 were determined
for 1 kb tiles on chr4 against the corresponding MethylC-seq data3 and stratiﬁed according to local CpG density. Mean log ratios of probes for chip
data or mean numbers of reads for seq data in the tiles were calculated and correlated to mean methylation scores of the MethylC-seq data (minimum 10
reads) using Pearson correlation. Missing-value tiles were excluded, and non-CG methylation sites in the H1 MethylC-seq data were removed before
averaging and correlation with the MRE-seq and MBD-seq data. Aggregate correlation numbers (r) obtained with each analytical procedure are
shown above the plots. (b) Three-way concordance analysis of mTAG-chip and MeDIP-chip approaches with MethylC-seq. Mean log ratios of the probes
in 1 kb tiles were calculated and a methylation type of a tile deﬁned as follows: weak methylation p25% of the signal distribution; partial methylation ¼
25%osignalo75% of the signal distribution; high methylation ¼ signal475% of the signal distribution. Concordance with the bisulﬁtome data
(at 45 reads) covering human chr4 þ chr15 þ chr18 was determined if the type matched with that of the MethylC-seq call; random calls give a
concordance of B0.375. Data stratiﬁed according to the number of CpG sites per tile. (c) Correlation of mTAG-chip and MRE-chip versus mTAG-seq using
Gaussian kernel smoothing. Gaussian kernel smoothing was used to examine Pearson correlations between mTAG-seq and mTAG-chip (click chemistry)
or MRE-chip data representing human brain DNA unmethylomes. In both cases, the correlation increases with increased kernel bandwidth until it
reaches a plateau at a bandwidth of around 1.9 kb for mTAG-seq and 3.1 kb for mTAG-chip data.

mTAG labelling using azide-alkyne cycloaddition. In the second
part of the study, we introduced a bioorthogonal copper-free clickreaction28 for mTAG labelling (Fig. 1b, bottom). The analytical
procedure remained essentially the same, except that a different
AdoMet analogue (Ado-6-azide, Supplementary Fig. S1a) and a
matching biotin reagent (DBCO-SS-biotin) were used in Step 2
and Step 3 (Fig. 1a), respectively. Control qPCR experiments using
the 200–230 bp DNA fragments showed a nearly identical
labelling efﬁciency but offered a 10-fold reduced background
labelling as compared with the previous conjugation (Fig. 1c).
Other technical parameters appeared identical with both
chemistries (Fig. 2; Supplementary Fig. S3) except that
ampliﬁcation of the enriched fragments after chemical cleavage
from the beads was slightly reduced in the latter approach
(20–25% drop in ampliﬁcation efﬁcacy over two targets sites
modiﬁed at High labelling intensity, Supplementary Fig. S4). At
Medium labelling intensity, an effect of similar magnitude would
be expected for fragments containing many (44) unmethylated
CpG sites. This slight impairment most likely derives from the fact
that a larger chemical group remains attached to the DNA after

the chemical cleavage of the S-S bond in the biotin linker (Fig. 1b),
which may impede a DNA polymerase during the initial cycles
of PCR. However, no detectable gross effect was reported in the
case of TAB-seq12 and TAmC-seq33 methods in which an even
bulkier linker group (glucose-azide-DBCO) remained in the
released DNA.
We further adapted the Click version of mTAG for large-scale
studies using a 96-well plate format (Supplementary Methods).
We then analysed mTAG-enriched gDNA samples on the
microarrays. Comparisons between mTAG-chip and MeDIPchip were made using gDNA from human brain and sperm. In
our hands, samples enriched with the mTAG technique displayed
better hierarchical clustering than MeDIP-enriched samples
(Supplementary Fig. S8). The MeDIP and mTAG technique
target different CG sites, methylated and unmodiﬁed, respectively. This was conﬁrmed in a tiling microarray experiment
examining chromosomes 10, 13, 14 and 17. As expected, negative
correlations were observed in the brain (r ¼  0.52) and sperm
(r ¼  0.35) samples between mTAG and MeDIP-chip probes
with high signal intensities.
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It was previously shown that certain bacterial C5-MTases can
catalyse sequence-speciﬁc removal of the 5-hydroxymethyl
group from a hmC residue yielding unmodiﬁed C34. If this also
occurs under conditions of mTAG labelling of gDNA, the
dehydroxymethylated CpG will be spuriously labelled as

unmodiﬁed cytosine, and enriched. In control experiments with
a PCR-generated 190 bp DNA fragment containing a single
modiﬁed CpG site, a low amount of labelling was detected
at the hmC, which became negligible in a reaction with pH ¼ 6.5
(Supplementary Fig. S9). To examine if this side reaction creates a

H1 methyIC-seq signal (Methylome)

Brin mTAG signal (Unmethylome)

15

Average signal

Average signal

0.6

10

5

0.4

0.2

0.0

0
Promoter 5′-UTR

Exons

Introns

Promoter 5′-UTR

3′-UTR

Exons

Introns

3′-UTR

CpG
CCGG
GCGC
CCGC

MRE sites

CpG Islands

Brain MeDIP
Brain MRE
Brain mTAG
MLH1

MRE sites

CpG
CCGG
GCGC
CCGC

CpG Islands
Brain MeDIP
Brain MRE
Brain mTAG
SHANK3

MRE sites

CpG
CCGG
GCGC
CCGC

CpG Islands
Brain MeDIP

Brain MRE

Brain mTAG
RepeatMasker

L2b
MRE sites

CpG
CCGG
GCGC
CCGC

CpG Islands
Brain MeDIP
Brain MRE

Brain mTAG
RepeatMasker

MLT1B

GC percent
Brain MRE
Brain MeDIP
Brain MTAG 1
Brain MTAG 2
Brain mTAG Input
SINE

AluSx1

6

AluSz

AluSx

AluSx3

AluY AluJb

AluSc8

NATURE COMMUNICATIONS | 4:2190 | DOI: 10.1038/ncomms3190 | www.nature.com/naturecommunications

& 2013 Macmillan Publishers Limited. All rights reserved.

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3190

measurable difference in human brain gDNA, which exhibits
higher hmC content compared with other tissues35,36, the DNA
was treated with M.SssI for an extended period of time. hmC sites
were measured before and after M.SssI treatment using an assay
where hmC glucosylation was coupled with MspI restriction
enzyme digestion37. The microarray data (chromosome 1 and 6,
Supplementary Fig. S10) showed that the number of hmC sites
detected in M.SssI-exposed and control samples is the same
within error, suggesting a negligible, if any, contribution of this
side reaction to genomic analyses. Although caC sites also show
some labelling in control experiments (Supplementary Fig. S9),
their extremely low abundance in gDNA36 should not affect
routine epigenomic studies.
We further assessed DNA unmethylome proﬁles in the postmortem human brain using the mTAG-seq approach. In this
experiment B100 million reads per sample were generated.
Biological and technical replicates showed similarity but were
clearly distinct from a non-enriched control in all validation
measures, including epigenome-wide pairwise correlation, mapping statistics, standard browser and whole-chromosome proﬁles
(Supplementary Figs S11–S14). The mTAG-seq results were also
globally compared with those of mTAG-chip and MRE-chip
experiments performed on the same brain gDNA samples. We
used Gaussian kernel smoothing, which takes into account
regional DNA modiﬁcation effects, and detected that correlation
between the microarray and mTAG-seq data sets gradually
increased and reached a maximum (r ¼ 0.78 and 0.49 for mTAGchip and MRE-chip, respectively) when the size of the kernel
bandwidth expanded to 1.9 kb for mTAG-seq and 3.1 kb for the
mTAG-chip data (Fig. 4c). The kernel bandwidths in the mTAGseq and mTAG-chip experiment distributed 50% of its weight in a
window of B1 and B1.5 kb, respectively, which likely reﬂects an
inherent 1–2 kb CpG co-methylation in the human genome38.
mTAG-seq and mTAG-chip correlation coefﬁcients varied
for different GC content regions (r ¼ 0.47, 0.85 and 0.75 for
probes with low, medium and high GC content, respectively;
Supplementary Fig. S15). MRE-chip showed a substantially
weaker overall correlation with mTAG-seq (r ¼ 0.44).
Consistent with the ability of mTAG to enrich for unmethylated genomic regions, the relative mTAG-seq density in the brain
throughout different gene-associated regions showed inverse
features compared with modiﬁed cytosine maps generated by
bisulﬁte-sequencing of the H1 cell line3 (Fig. 5a). At the level of
individual genes, mTAG-seq proﬁles of typical protein coding
genes showed that the promoters and CpG islands were
unmethylated, consistent with high MRE-seq and no MeDIPseq signal (Fig. 5b). We also demonstrated that the mTAG
approach can identify and map the unmodiﬁed genomic

retroelements. L2b, a non-long terminal repeat retrotransposon
(chr19: 41257434–41257808, 11 CpGs), appeared to be
unmethylated in the brain as supported by the lack of MeDIP
reads and a detectable peak in the MRE proﬁle (Fig. 5c). Another
example, MLT1B—a mammalian long terminal repeat
retrotransposon (chr14: 106804419–106804800, 3 CpGs), was
not detectable by MRE due to the scarcity of suitable restriction
endonuclease sites and had a very weak MeDIP signal (Fig. 5c). In
both cases, strong mTAG signals illustrated a positive display of
these fairly abundant differentially modiﬁed DNA retroelements.
A more complex situation is shown in Fig. 5d where seven SINE
elements were marked by both mTAG-seq and MeDIP-seq in the
brain samples, suggesting their intra-individual epigenetic
variation.
Discussion
Here we describe the ﬁrst approach for covalent capture and
mapping of the DNA unmethylome. As unmodiﬁed cytosines
represent a smaller proportion of CpG sites compared with
methylated ones (depending on the tissue, over 70% of cytosines
in the human genome are methylated29), analysis of this smaller,
unmethylated DNA fraction may reduce the number of statistical
comparisons and is more sensitive for detecting subtle epigenetic
changes5. Taking also into account, the occurence of the other
modiﬁed cytosines (hmC, fC, caC), which cannot be easily
differentiated from mC and C, our approach provides a unique
cross-section through the complex chemical landscape of the
mammalian epigenome.
Furthermore, MeDIP and MBD enrichment have been noted
to have a substantial CpG coverage bias towards the highly
methylated sequences16,17,31. Based on our decile correlation
analyses, mTAG shows its strength in low and intermediate
CpG density genomic regions, which comprise 480% of the
genome and over 50% of all CpG sites, and which are
insufﬁciently covered by the existing techniques. Such regions
include enhancer elements, CpG island shores and promoters
of cell type-speciﬁc genes, which often undergo dramatic changes
in CpG modiﬁcation status during cell differentiation and
development39–42, and which are candidate markers of diseases
such as cancer43. Moreover, mTAG can be considered not
only as a powerful and cost-effective alternative, but also as a
complementary technique to 5mC-speciﬁc methods such as
MeDIP and, likely, to a newly described covalent method, TAmCseq33. mTAG-seq proﬁling permitted positive identiﬁcation of
unmethylated and partially methylated transposable elements,
which are often left behind using MRE and MeDIP analyses.
Although transposons and repetitive elements are commonly

Figure 5 | Epigenomic mTAG-seq proﬁles of human brain DNA. (a) mTAG-seq and MethylC-seq proﬁles over a mega-gene. Left, mTAG-seq signal
density (unmethylome) displayed with GenePlot50 throughout different gene-associated regions. Gene annotations were obtained from UCSC Genome
Browser. Promoter was deﬁned as 1 kb upstream from transcript start site. Promoters, transcription start sites and 50 -UTRs all displayed increased
mTAG-seq signal compared with gene bodies, consistent with hypomethylation of these regions. Right, MethylC-seq proﬁle (methylome) of H1 human
embryonic stem cells over a composite gene (replot of Fig. 3a from Lister et al.3). (b) mTAG-seq proﬁle of two typical protein coding genes. Genome
browser view of mTAG-seq data over typical genes in comparison to MeDIP-seq and MRE-seq of the brain51. The upper panel displayed MLH1, and the
lower panel displayed SHANK3. Promoters of both genes were unmethylated, consistent with high mTAG-seq, high MRE-seq, and no MeDIP-seq signal.
The gene body of SHANK3 contained several unmethylated CpG islands, which exhibited high mTAG-seq signal. (c) Unmethylated retroelements
revealed by mTAG-seq. Genome browser view of two retroelements. The upper panel displayed L2b. The element was marked by high mTAG-seq, high
MRE-seq and low MeDIP-seq signal. These three methods were in agreement in supporting the unmethylated status of the element. The lower panel
displayed MLT1B. The element was marked by high mTAG-seq and low MeDIP-seq signal, indicating a hypomethylated status. MRE-seq produced no signal
over this region due to the low abundance of restriction endonuclease sites. (d) Partially methylated retroelements revealed by mTAG-seq. Genome
browser view of seven SINE elements. These elements were consistently marked by mTAG-seq in two brain samples;the same elements displayed a
MeDIP-seq signal, altogether suggesting they were partially methylated (contained both unmodiﬁed and methylated CpGs). A non-enriched input track
(mTAG Input) was also shown indicating that the coenrichment of the MeDIP-seq and mTAG-seq signals over these SINE element was not an artifact of
sequence alignment.
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thought to be heavily methylated3,44, some of them show a loss in
methylation in cancer45 or in response to other developmental
cues, and may thus be of high predictive and diagnostic value.
The input quantity of human gDNA (100–300 ng) required for
whole-genome mTAG analysis was at the lower end of typical
samples consumed for MethylC-seq (5 mg), MeDIP-seq (0.1–5,
typically 41 mg) or MethylCap-seq or MBD-seq (1–3 mg)46,47,
owing to the covalent labelling, tight afﬁnity capture and mild
chemical release employed in the enrichment procedure. The
analytical procedure is robust and well adaptable for highthroughput epigenomic studies. Both the conventional and click
versions of the method allow for efﬁcient unmethylome analyses,
although due to its very low nonspeciﬁc labelling, the latter
appears to be the method of choice for large-scale populational
studies. The mTAG technology thus brings a new analytical
platform with its follow-up application-driven modalities,
providing a valuable addition to the toolbox of epigenomic
studies.
Methods
AdoMet analogues. AdoMet analogues (Supplementary Fig. S1a) were obtained
by S-selective coupling of 4-nitrophenylsulfonyl-activated side chains to S-adenosyl-L-homocysteine26. Ado-6-amine was isolated as a diastereomeric mixture
containing B50% of the enzymatically active S,S-diasteromer. For Ado-6-azide, the
enzymatically active diasteromer was isolated by reversed-phase HPLC.
Genomic DNA. DNA from sperm and post-mortem (prefrontal cortex) human
brains were puriﬁed using standard phenol–chloroform extraction. Human ﬁbroblast IMR90 gDNA was kindly provided by R. Lister or obtained from the UK
Health Protection Agency. Brain samples were received from the Harvard Brain
Tissue Resource Center. Sperm samples were collected at the Krembil Family
Epigenetics laboratory, Centre for Addiction and Mental Health, Toronto. Centre
for Addiction and Mental Health Research Ethics Ofﬁce approved the study under
the protocol number 175-2009. All of the patients and relatives gave informed
consent for the use of tissues.
qPCR analysis. DNA probes for qPCR monitoring of DNA recovery were prepared by PCR ampliﬁcation of C57BL/6 mouse gDNA with corresponding primers
(Sp-PCR-dir, 50 -GTGTTGGGGTGACTATTATGAND-30 Sp-PCR-rev, 50 -CCTATACTCAGCGCATCC-30 for the speciﬁc probe, and Ns-PCR-dir, 50 GCCCACTTCACTTCTTGTGAND-30 Ns-PCR-rev, 50 -AGGCCAAAAGAAAGAAGAGAT-30 for the nonspeciﬁc one). Reverse transcriptase PCR experiments
were performed with a Rotor-Gene 6000 real-time PCR system (Corbett Research)
using a Maxima Probe qPCR Master Mix (ThermoFisher). Primers (0.3 mM)for the
speciﬁc DNA fragment, 1 mM primers for the nonspeciﬁc probe and 250 nM of the
respective dual-labelled probe were used in each reaction. The ampliﬁcation program was set as: 95 °C for 10 min, 40 cycles 95 °C for 15 s, 60 °C for 1 min. Primer
sequences are listed in Supplementary Table S2.
mTAG-directed biotin labelling and enrichment of DNA. gDNA was sonicated
on a Bioruptor UCD-200 (Diagenode) in EB buffer (10 mM Tris-HCl (pH 8.5) for
2 h to yield fragments with a peak size of 250 bp. Sheared DNA was end-ﬁlled using
the DNA End Repair Kit (ThermoFisher) and DNA was puriﬁed using a QIAquick
Nucleotide Removal kit (Qiagen).
For mTAG labelling using amine-NHS chemistry, reactions of 25 ml contained
100–300 ng of sheared and blunt-ended gDNA (and optionally 50 ng of qPCR
reference fragments), 50 mM of freshly diluted cofactor analogue Ado-6-amine and
engineered eM.SssI (no enzyme for 0% labelling intensity; 45 nM for Low labelling
intensity; 180 nM for Medium labelling, or 1440 nM for High labelling) in M.SssI
reaction buffer (10 mM Tris-HCl pH 7.6, 50 mM NaCl, 0.1 mg ml  1). Reactions
were incubated at 37 °C for 30 or 60 min, followed by heating at 65 °C for 15 min.
DNA samples were puriﬁed using a QIAquick Nucleotide Removal kit and treated
with 8.6 mM biotin disulphide N-hydroxysuccinimide ester (NHS-SS-biotin,
Sigma) in 0.15 M sodium bicarbonate (pH 9.0) at room temperature for 2.5 h, and
again puriﬁed with a QIAquick Nucleotide Removal kit. For mTAG-click labelling
using azide-alkyne conjugation, 25 mM Ado-6-azide cofactor and eM.SssI (90 nM
for Medium labelling, or 180 nM for High labelling) were used. Reactions were
incubated at 37 °C for 30 or 60 min, followed by heating at 80 °C for 10 min.
Dibenzylcyclooctyne-SS-PEG11-Biotin or dibenzylcyclooctyne-SS-PEG3-BiotinConjugate (Jena Bioscience) was then added to 0.2 mM concentration and
incubated at 37 °C for 2 h.
The mixture of the Dynabeads MyOneC1 Streptavidin (0.1 mg) and DNA
recovered after biotinylation step were incubated in 10 mM Tris-HCl (pH 8.5), 1 M
NaCl buffer at room temperature for 3 h on a roller. Beads were washed 3  with
8

washing buffer A (10 mM Tris-HCl (pH 8.5), 3 M NaCl); 2  with washing buffer
B (10 mM Tris-HCl (pH 8.5), 1 M NaCl) and ﬁnally resuspended in 100 mM
Tris-HCl pH 7.4. For recovery of enriched DNA fraction, DNA-bound beads were
incubated in 200 mM DTT at room temperature for 1 h, and released DNA was
precipitated with propanol-2. DNA pellet was resuspended in 9 ml of 1xT4 DNA
Ligase buffer (ThermoFisher) and ligated to double-stranded adaptors as indicated
below.
PCR ampliﬁcation of enriched DNA for microarray analysis. PCR adaptors were
prepared by annealing equal amounts (100 mM) of single-stranded oligonucleotides
A-25 (50 -AGTTACATCTTGTAGTCAGTCTCCA)-30 and A-19 (50 -TGGAGACT
GACTACAAGAT)-30 in T4 DNA Ligase buffer. To ligate adaptors to gDNA
fragments, DNA recovered from beads was incubated with 5 mM adaptors
at 45 °C for 10 min, the mixture was chilled on ice and after addition of 5 a.u.
of T4 DNA Ligase (ThermoFisher) was further incubated at 22 °C overnight.
For PCR ampliﬁcation, adaptor-ligated DNA was incubated with 100 mM
2-mercaptoethanol for 10 min at room temperature (to preclude inadvertent
formation of inter-nucleotide disulphide cross-links), followed by PCR in Taq
Buffer with (NH4)2SO4 supplemented with 0.2 mM deoxyribonucleotide (dNTP),
1 mM MgCl2, 1 mM A-25 oligonucleotide and 5 a.u. Taq DNA Polymerase
(ThermoFisher). PCR cycling conditions: 1 min 50 °C, 5 min 72 °C, 4 min 94 °C, 15
cycles of 1 min 94 °C, 1 min 65 °C, 1 min 72 °C and the ﬁnal extension step is at
72 °C for 2 min. For mTAG-click-labelled DNA, the extension step of the ﬁrst cycle
was prolonged to 5 min to alleviate the possible impairment of PCR ampliﬁcation
because of bulky groups left on DNA (see Fig. 1).
Microarray analysis. For microarry hybridization experiments,an aliquot of 1/10
the above ampliﬁed DNA sample was used as template in a second-round PCR that
contained dUTP as speciﬁed in the WT Double-Stranded DNA Terminal Labelling
Kit (Affymetrix). The reaction was carried out with 200 pmol of adaptor-speciﬁc
A-25 primer, 2.5 mM MgCl2, 0.4 mM dNTPs with 0.02 mM dUTP, and 5 a.u. Taq
polymerase (New England Biolabs). The PCR ampliﬁcations were performed at
95 °C for 1 min followed by 15 cycles of 94 °C for 15 s, 65 °C for 30 s and 1 min at
72 °C, with an extension of 5 s at the last step of each subsequent cycle.
For the microarray hybridization, 9 mg of puriﬁed uracil-containing amplicons
were fragmented to 50–100 bp using GeneChip Double-stranded DNA Terminal
Labelling kit (Affymetrix). Individual samples were hybridized to a separate
GeneChip Human Tiling 2.0 R Arrays. The arrays were washed, stained and
scanned using an Affymetrix GeneChip Scanner as described in the Affymetrix
ChIP Assay protocol. Array data was quantile normalized, and mTAG log ratios for
unlabelled (0% labelling) over labelled (5–80% labelling) probes were generated.
MeDIP analysis6 of IMR90 gDNA was performed as follows. Two replicate
samples were prepared using the MagMeDIP kit (Diagenode) according the
manufacturer’s instructions. An aliquote of each sample was used as a template in
two independent PCR reactions to conﬁrm enrichment of methylated and
depletion of unmethylated sequences, relative to fragmented input DNA. The
enriched samples were further ampliﬁed using a WGA kit (Sigma) and analysed on
microarrays as described.
Comparisons between MeDIP-chip and mTAG-chip. gDNA from three brain
and ﬁve sperm samples were processed in a mTAG and MeDIP protocol (three
replicates per sample and protocol). Steps 1–5 of mTAG enrichment were performed as described in the high-throughput mTAG-click protocol (Supplementary
Methods). Samples in 50 mM DTT, 60 mM Tris pH 7.8 were dA-tailed in a
reaction containing 0.2 mM dATP, 5 mM MgCl2, 5 mM Tris pH 7.8 and 5 a.u.
Klenow, exo- (Thermo Scientiﬁc). Aten-fold molar excess of adaptor was ligated to
DNA fragments. Adaptors had been prepared by annealing equimolar amounts of
each primer (Ad1, 50 -[phos]-GATCGGAAGAGCACACGTCT-30 and Ad2, 50 ACACTCTTTCCCTACACGACGCTCTTCCGATCT)-30 . Ligation of adaptors to
the DNA fragment was performed overnight at 22 °C in a 30 ml volume in Buffer
(6 mM MgCl2, 0.5 mM ATP) and 10 a.u. T4 DNA ligase. Puriﬁcation of samples
was completed with the ZR-96 DNA Clean & Concentrator-5 kit (Zymo Research).
Samples were then incubated with 32 mM 2-mercaptoethanol for 10 min at room
temperature. PCR ampliﬁcation was performed in two rounds. Initially, samples
were combined with buffer (75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01%
Tween 20), 1 mM MgCl2, 200 mM dNTPs, 0.5 mM of each primer (Ad-F, 50 -AATG
ATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCT-30 , Ad-R, 50 -GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT)-30
and 6.3 a.u. Taq polymerase (ThermoFisher) in a reaction volume of 100 ml. The
second PCR step (using the Ad-F and Ad-R primers) and PCR cycling conditions
were performed as described in the high-throughput mTAG-click protocol.
In the MeDIP experiment, samples were dA-tailed and ligated to the same
adaptors. Ligated DNA was puriﬁed with Ampure XP beads (Agencourt).
Approximately 800 ng of each sample, including antibody negative controls, were
processed using the MagMeDIP kit (Diagenode), following the manufacturer’s
instructions. Kit internal controls were evaluated using qPCR, and all MeDIP
samples indicated a speciﬁcity that exceeded 98%. MeDIP-treated samples were
then PCR-ampliﬁed in a two-step procedure (10 PCR cycles in step one and 6 PCR
cycles in step two) as in the mTAG approach described above.
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MeDIP and mTAG samples were normalized separately as follows. First,
interarray correlations (IACs) were assessed to identify and remove outlying
samples48. Log2 scaled raw intensity values of samples were correlated with one
another. These IACs were averaged for each array and compared with the resulting
distribution of IACs. Samples with an average IAC of more than two s.d. values
below the mean IAC were considered outliers and removed in repeat cycles. Next,
samples were quantile normalized, mean total input was subtracted and probes
from repetitive regions were removed. Adjacent probes were smoothed using 3.1 kb
Gaussian kernel. To assess the clustering of samples, 300,000 most variable probes
among mTAG and MeDIP samples were selected separately and their union was
used. Distance between samples was deﬁned as inverse of a scaled Pearson
correlation. Hierarchical clustering with average linkage was employed to produce
the clustering dendrogram. Average Pearson correlation of matching MeDIP and
mTAG samples was quantiﬁed using 20% most intense probes.
mTAG-seq. Nine brain samples (from eight different individuals plus one technical replicate) were sheared at an average length of 300 bp and labelled using the
mTAG approach as described in the high-throughput mTAG-click protocol. The
puriﬁed mTAG-enriched samples, along with a sheared aliquot of a sample that
was not enriched in the mTAG procedure (total input), were then submitted to the
Beijing Genomics Institute (BGI) for ﬁnal library preparation and sequencing.
Library preparation involving adenylation of 30 -ends, adaptor ligation and PCR
ampliﬁcation with unique index primers was performed as described in the
Illumina Multiplexing Sample Preparation Oligonucleotide kit. The only changes to
this library preparation protocol were that the samples were treated with 10 mM 2mercaptoethanol for 10 min at room temperature before PCR ampliﬁcation, and
only 14 cycles of PCR were performed. Paired-end sequencing was completed on
an Illumina HiSeq platform generating B100 million paired-end reads for each
mTAG-seq library, with a read length of 90 bp. These reads were mapped to the
human genome assembly hg19 using BWA49 with default parameters. Sequencing
reads from female samples were mapped to the same reference with chromosome Y
excluded. Alignments with mapping quality score greater or equal to 10 were
considered unique alignments. Alignments mapped to exactly the same genomic
location were considered as redundant reads resulted from PCR ampliﬁcation
and were removed from further analysis. The non-redundant, uniquely mapped
sequence fragments were further processed using in house tool iteres (http://
epigenome.wustl.edu/iteres/) to generate read density ﬁles. These read density ﬁles
were uploaded to both the UCSC Genome Browser (http://genome.ucsc.edu)
and the Washington University Epigenome Browser (http://epigenomegateway.
wustl.edu) for visualization and further analysis.
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